Blood cancer treatment sales will expand through 2036, with chemotherapy holding a 35.0% share as the leading application segment. The market value stood at USD 7.1 billion in 2025 and is forecast to reach USD 18.4 billion by 2036 across key growth regions including China, the USA, and India.